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1. Introduction 
Chemo- and immunotherapeutic approaches have been used to prevent recurrence of 
transitional cell carcinoma (TCC), the most common type of superficial bladder cancer 
(SBC). The bacillus Calmette-Guérin (BCG) vaccine for tuberculosis, which consists of an 
attenuated form of Mycobacterium bovis, is the most commonly used immunotherapeutic 
agent (Morales et al., 1976). Despite the successful results achieved with BCG, its serious 
side effects have led researchers to investigate other immunostimulatory substances. In the 
early 1970s, Olsson and collaborators reported that subcutaneous stimulation with keyhole 
limpet hemocyanin (KLH) from the Californian marine gastropod Megathura crenulata 
significantly reduced SBC recurrence frequency in TCC patients without any toxic side 
effects, making it ideal for long-term repetitive treatments (Olsson et al., 1974). These results 
provided promising support for the use of mollusk hemocyanins as alternative agents in 
SBC immunotherapy.  
Hemocyanins, blue respiratory glycoproteins that were discovered in 1878 by Léon 
Fredericq (Ghiretti-Magaldi & Ghiretti, 1992), are found freely dissolved in the blood of 
some mollusks and arthropods. These proteins are giant structures with molecular weights 
between 4 and 8 MDa, and they exhibit some of the most complex and sophisticated 
quaternary structures known. Hemocyanins are part of the type-3 group of copper proteins 
that includes phenoloxidases and tyrosinases (Decker & Tuczek, 2000). These proteins 
contain active copper-containing sites in which the Cu(I,I) state is oxidized to the Cu(II,II) 
state, thus accounting for their distinctive deep blue color. Because of these properties, the 
biochemistry of hemocyanins has been intensively studied (van Holde & Miller, 1995). The 
pioneering work of Weigle in the 1960s on the immunochemical properties of KLH 
demonstrated its remarkable immunostimulatory properties in an experimental animal 
model (Weigle, 1964). These results were quickly incorporated into clinical studies to 
evaluate its immunological effects.  
Because the primary amino acid sequences of mollusk hemocyanins are highly divergent 
from mammalian sequences, they are strongly recognized by the immune system, resulting 
in potent immunogenicity; these proteins can be used therapeutically as non-specific 
immunostimulants with beneficial clinical outcomes. Moreover, hemocyanins have been 
extensively used as carriers to generate antibodies against diverse hapten molecules and 
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peptides and to induce antigen-specific CD8+ and CD4+ T cell responses (Harris & Markl, 
1999). Currently, hemocyanins are used as carrier-adjuvants for several tumor-associated 
antigens (TAAs), such as glycolipid and glycoprotein (mucin-like) antigens, in experimental 
therapeutic vaccines against certain cancers, including melanomas, sarcomas, breast, 
prostate, ovary and lung (Musselli et al., 2001; Schumacher, 2001; Zhu et al., 2009; Del 
Campo et al., 2011). Other therapeutic strategies that use hemocyanins include dendritic cell 
(DC) vaccines pulsed with tumor lysates to enhance interferon gammaIFN- production 
by tumor-reactive T cells (Timmerman & Levy, 2000; Shimizu et al., 2001; Millard et al., 
2003; Lopez et al., 2009; Jacobs et al., 2010; Lesterhuis et al., 2011) and anti-idiotype vaccines 
for some types of B cell malignancies (Leitch & Connors, 2005; Kafi et al., 2009). KLH has 
been the gold standard for these applications for over 40 years simply because it was used in 
earlier studies instead of other hemocyanins (Harris & Markl, 1999). The first studies used a 
research-grade KLH (non-GMP) containing different levels of endotoxin (Vandenbark et al., 
1981); since then, several companies have produced clinical-grade KLH. 
The versatile properties of KLH in biomedical and biotechnological applications have led to 
increasing commercial demand and growing interest in finding new, alternative 
hemocyanins with similar or more potent immunomodulatory properties. Although the 
KLH gene has been cloned, and its amino acid sequence is known, it has not been possible 
to express a heterologous protein, mainly because of its complex structure (Lieb et al., 2001; 
Markl et al., 2001; Altenhein et al., 2002). Therefore, this protein can be obtained only from 
its natural source. Several hemocyanins from other species of mollusks have been studied 
biochemically and immunologically, including Haliotis tuberculata (HtH, Abalon) (Markl et 
al., 2001); Helix vulgarix (HpH, Vineyard snail), Rapana venosa (RvH, Asian rapa whelk), and 
Rapana thomasiana (RtH, Black sea murex) (Dolashka-Angelova et al., 2003; 2008; 2010); and 
Concholepas concholepas (CCH, Loco), which is found on the pacific Chilean coast (De Ioannes 
et al., 2004). Only CCH has been pre-clinically evaluated in a murine experimental model of 
SBC and may be considered a safe alternative therapy (Moltedo et al., 2006; Atala, 2006). 
Although KLH and CCH have different origins and structure they have similar 
immunostimulatory capacities, suggesting that a conserved pattern common to both 
hemocyanins induces an ancient immunological mechanism (Moltedo et al., 2006). 
Interestingly, we have described a new hemocyanin from Fissuerella latimarginata (FLH) that 
exhibits higher immunogenicity than either CCH or KLH, opening a new avenue for 
research on the use of hemocyanins (Espinoza et al., 2006; Arancibia et al., 2010). 
Notwithstanding the biomedical interest in mollusk hemocyanins, the molecular and 
cellular bases of their adjuvant/immunostimulatory capacity in SBC remain poorly 
understood. Currently, we know that hemocyanins are able to drive the differentiation of T 
helper (Th) cells toward a Th1 phenotype, characterized by increased secretion of IFN-γ and 
the production of IgG2a isotype antibodies (Moltedo et al., 2006).  
In this chapter, we will review what is currently known about the experimental and clinical 
uses of mollusk hemocyanins as non-specific immunostimulants to prevent SBC recurrence, 
including the details of their intricate structure and the immunologic mechanisms that have 
been proposed to explain their antitumor activity. 
2. Structure of the mollusk hemocyanins  
Because of their enormous size, mollusk hemocyanins are easily observed by transmission 
electron microscopy (TEM) using negative staining. These molecules have a cylindrical form 
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with an external diameter of approximately 350 nm and length of approximately 400 nm. 
Fig. 1 shows the characteristic appearance of gastropod hemocyanins under TEM. 
 
 
Fig. 1. Electron microscopy of negatively stained C. concholepas hemocyanin molecules. A. 
Low magnification micrographs of a preparation of the protein showing their characteristic 
hollow cylinder form. The images show the top (circles) and lateral (rectangles) views of the 
molecule. The arrow shows a decamer. B. High magnification images of hemocyanin 
molecules showing their intricate structure. The side views show the proteins’ characteristic 
didecameric form with subunits arranged in layers. 
Many experimental studies on hemocyanins, using different dissociation and association 
conditions and physicochemical and biochemical methods, have helped to elucidate their 
hierarchically organized structure (van Holde & Miller, 1995; Harris & Markl, 1999). As 
shown in Fig. 2, the basic structure of hemocyanins is composed of ten subunits that are self-
assembled into a hollow cylinder, a structure known as a decamer, with a lumen that is 
narrowed by a complex collar (Harris et al., 1993; Cuff et al., 1998; Decker et al., 2007). In 
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gastropods, the decamers can self-associate face-to-face to form stable dimers or didecamers, 
which display an intricate internal arrangement and result in the formation of extremely 
large structures with approximate D5 symmetry (Orlova et al., 1997). Hemocyanin subunits 
have a molecular weight ranging from 350 to 450 kDa and are composed of a string of seven 
or eight globular domains called functional units (FUs), each with a molecular weight 
between 35 and 50 kDa. These FUs are connected by a short flexible linker peptide strand of 
10 to 15 amino acid residues. Each FU has two well-separated copper atoms that reversibly 
capture O2 molecules; one is called the A site, which is located towards the N-terminus, and 
the other is called the B site and is located downstream of the polypeptide (van Holde et al., 
2001).  
 
 
Fig. 2. Model of the structure of mollusk hemocyanin. The basic structure of a mollusk 
hemocyanin is a decamer, which is formed by the association of 10 polypeptides or subunits. 
In hemocyanins from some species of mollusk, such as gastropods, including KLH and 
CCH, the decamers are associated in pairs to form very large molecules called didecamers.  
The subunit consists of seven or eight globular domains linked by a peptide spacer 
consisting of 10 to 15 amino acid residues, similar to a pearl necklace. Each of these globular 
domains has a pair of copper atoms that reversibly bind one oxygen molecule, which is why 
they are called functional units. 
Knowledge of the carbohydrate moieties present in mollusk hemocyanins has been essential 
for understanding their organization, antigenicity and biomedical properties (Paccagnella et 
al., 2004; Siddiqui et al., 2007). In fact, several authors have reported that hemocyanin 
carbohydrates may play a role in their immunostimulatory effects. The high carbohydrate 
content of hemocyanins, up to 9% (w/w), has been measured by different methods, including 
the use of lectins and high-pressure liquid chromatography–tandem mass spectrometry 
(HPLC-MS/MS). The presence of numerous N-glycosylation sites and a reduced number of O-
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glycosylation sites has been established (Dolashka-Angelova et al., 2003; Gielens et al., 2004; 
Idakieva et al., 2004; Gatsogiannis & Markl, 2009; Dolashka et al., 2010). Mollusk hemocyanins 
contain diverse sugar moieties, including mannose, D-galactose, fucose, N-acetyl-D-
galactosamine and N-acetyl-glucosamine residues, with mannose being the most abundant 
(Harris & Markl, 1999). Hemocyanins also contain monosaccharides that are not usually found 
in animal proteins, such as xylose (Lommerse et al., 1997). 
2.1 KLH and CCH 
Although KLH and CCH each have two subunits that constitute the basic structure known 
as a decamer, closer analysis revealed unique differences. Native gel electrophoresis has 
shown that KLH is made up of two different non-covalently linked subunits called KLH1 
(350 KDa) and KLH2 (350 KDa) that do not display shared epitopes (Swerdlow et al., 1996). 
Using the same approach, it was demonstrated that CCH is also made up of two different 
subunits, CCHA (405 kDa) and CCHB (350 kDa), that contain common and specific epitopes 
(Oliva et al., 2002; De Ioannes et al., 2004). In KLH, the subunits form homodidecamers (i.e., 
the molecules are formed from either KLH1 or KLH2 subunits). However, in CCH the 
subunits form heterodidecamers (i.e., the molecules are formed by pairing the two different 
subunits). In addition, purified KLH requires divalent cations in storage buffers to maintain 
the stability of its quaternary structure, whereas CCH does not (De Ioannes et al., 2004); this 
is probably a consequence of the higher hydrophobicity of CCH (Leyton et al., 2005). 
Despite these differences, the immunogenic properties of CCH and KLH are similar. CCH 
has been successfully used as a carrier protein to generate antibodies against hapten 
molecules and peptides (Becker et al., 1998; Torres et al., 1999; Mura et al., 2002; Duvillie et 
al., 2003; Manosalva et al., 2004; Cancino et al., 2007; Gravotta et al., 2007; Matus et al., 2007; 
Grenegard et al., 2008); as a carrier in vaccines (Miller et al., 2006; Mauldin & Miller, 2007; 
Pilon et al., 2007) and as an experimental antigen (Becker et al., 2007; Moltedo et al., 2009). 
Several studies have demonstrated that KLH contains approximately 3.2% (w/w) 
carbohydrate residues, displaying specific structural motifs on N-glycans, such as 
Fuc(alpha1-3)GalNAc, Gal-(beta1-6)Man-, Gal(beta1-4)Fuc-, and Gal(beta1-4)Gal(beta(1-
4)Fuc-, which are thought to contribute to its non-specific immunostimulatory capacities in 
SBC (Wuhrer et al., 2004). Our knowledge of the corresponding oligosaccharide composition 
of CCH is very limited. However, we have demonstrated using selective glycosidase 
treatments and electrophoretic analysis that sugar moieties account for 3.1% (w/w) of the 
mass of CCH. A comparative analysis using lectin staining indicated that mannose is the 
only exposed carbohydrate common to CCH and KLH (Becker et al., 2009). It is important to 
note that, despite the differences in carbohydrate composition between KLH and CCH, both 
proteins have similar immunogenicity and immunotherapeutic capacity in SBC, suggesting 
that other factors are responsible for this effect. We assume that the primary structure of 
these proteins contains the determining factor because they share regions of high sequence 
homology (van Holde et al., 2001; Manubens et al., 2010). These regions were confirmed in 
antibody cross-reactivity experiments that revealed the presence of common or mimetic 
epitopes in CCH and KLH (Oliva et al., 2002).  
3. Use of hemocyanins in experimental SBC 
Rats and various strains of mice have been used as in vivo SBC models to evaluate 
therapeutic agents because bladder tumors in these rodents have similarities with human 
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tumors. In addition, tumor cells can be established subcutaneously (heterotopically) or in 
the bladder (orthotopically) by either transplantation or chemical induction, allowing the 
investigation of clinical aspects such as pharmacokinetics and toxicity (Gunther et al., 1999; 
Linn et al., 2000; Arentsen et al., 2009).  
The first controlled study of a hemocyanin as immunotherapy in the treatment of superficial 
bladder cancer was published in the 1980s by the Lamm group (Lamm et al., 1981). They 
developed the mouse bladder tumor-2 cell (MBT-2) transplantable murine model of SBC 
and demonstrated that pre-immunization with 200 µg of KLH three weeks prior to 
subcutaneous injection with MBT-2, followed by intralesional immunotherapy with 50 µg 
one and seven days after inoculation, resulted in a significant reduction in tumor growth 
and a prolongation of animal survival. Later, other studies by the same researchers 
evaluated non-specific immunotherapeutic regimens (Lamm et al., 1982). Animals received 
an intradermal MBT-2 inoculation, and the immunotherapy was administered 
intralesionally one day after tumor transplantation. Tumors were excised at a volume of 400 
mm3, and the animals were re-challenged with tumor cells, treated again, and followed for 
tumor incidence, growth rate and survival. This study demonstrated that KLH had a weak 
antitumor effect compared with the response to BCG. In 1986, Lau and collaborators studied 
the same response, this time comparing intraperitoneal and intralesional administration of 
the agents. C3H/He mice were injected subcutaneously with 5 x 104 tumor cells. After that, 
the mice received either intraperitoneal or intralesional treatments (50 μg KLH); these 
experiments demonstrated that the intralesional route was more effective than 
intraperitoneal administration for tumor growth inhibition (Lau et al., 1986).  
Lamm´s group also evaluated the possible additive and/or synergistic effects of KLH 
immunotherapy in the MBT-2 model in conjunction with other treatments, such as IFN-α. 
Tumor cells were transplanted subcutaneously without prior immunization. Treatment was 
given intraperitoneally twice weekly for three weeks, except for BCG, which was 
administered once a week. Significant reductions in tumor incidence relative to the controls 
were observed in groups receiving KLH (42%), IFN-α (42%) and KLH + IFN-α (17%) (Riggs 
et al., 1992). The following year, the same group compared two alternative immunotherapies 
in the MBT-2 model: crude KLH and Immucothel, a clinical-grade KLH from Biosyn 
Arzneimittel GmbH. Mice were sensitized with 50 or 100 μg KLH, and 21 days later, 103 
tumor cells were injected. Intralesional treatment with 50 or 100 μg KLH was performed on 
days 1, 7 and 13 or 14. Crude KLH required either immunization before tumor transplant or 
frequent therapy after transplantation to be effective. In addition, Immucothel required pre-
immunization to be effective, even with an increased frequency and dosage of the post-
transplant immunizations. In a subsequent study, the endotoxin contamination of KLH was 
demonstrated to be partly responsible for the antitumor activity because treatment with 
endotoxin alone resulted in a significant reduction of tumor growth and mortality (50% 
survival) (Lamm et al., 1993). Moreover, KLH + 100 Endotoxin Units (EU) resulted in 
complete inhibition of tumor growth and 100% survival. KLH + 1000 EU appeared to reduce 
the antitumor response (50% survival), suggesting that endotoxin may interfere with the 
response to purified KLH. Finally, endotoxin-free KLH induced antitumor responses (50% 
survival). However, pre-immunization was required for KLH to exert a significant (75% 
survival) antitumor effect (Lamm et al., 1993). 
Walsh and collaborators studied KLH immunotherapy in two different models with no 
promising results. First, they transplanted 2.5 x 106 MBT-2 tumor cells subcutaneously after 
pre-immunization 20 days prior. Treatment was given on days 1, 8 and 18 in the form of 
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subcutaneous or intralesional injection of 50 µg KLH. The results showed no difference 
between the control and treated groups in terms of either tumor growth or animal survival. 
Alternatively, they transplanted 2.1 x 106 MBT-2 tumor cells into the bladder of C3H/He 
mice. The bladder was irrigated with 1.5 mg N-methyl-N-nitrosourea 48 hours prior. The 
treatment group was injected with 50 µg KLH on day 1, and the bladders were instilled with 
200 µg KLH on days 14 and 21. There was no significant difference from the control group 
(Walsh et al., 1983). Using a similar model, Marsh and collaborators demonstrated that 
intravesical immunotherapy with Corynebacterium parvum and Allium sativum was more 
effective than KLH and slightly more effective than BCG. MBT-2 cells were delivered into 
the bladder transurethrally using a small catheter, and the immunotherapy was 
administered directly into the bladder via this catheter on day 1 or day 6, or both. The 
authors associated the lack of a significant effect with inappropriate dosage or insufficient 
stimulation of the immune system (Marsh et al., 1987). Later, the antitumor activity and 
potential toxicity of a clinical grade KLH preparation named KLH-Immune Activator (KLH-
IA) was examined. Mice were immunized subcutaneously with KLH-IA two weeks prior to 
intravesical implantation with 2 x 104 MB-49 tumor cells. Treatment consisted of intravesical 
KLH-IA (10 or 100 µg) 1, 4, 7, 14 and 21 days after implantation. By four weeks after 
implantation, tumor outgrowth in the treated groups was significantly decreased. Prior 
subcutaneous immunization was required to elicit the antitumor activity of KLH-IA. 
Animals treated with a dissociated form of KLH showed decreased tumor outgrowth, but 
this was not significant. A separate toxicity study in which KLH-IA was given 
subcutaneously (4 mg/kg), intraperitoneally (40 mg/kg) or intravesically (40 mg/kg) 
reported no significant gross or histopathological abnormalities, except for mild to moderate 
papillary hyperplasia in all catheterized animals (Swerdlow et al., 1994). 
A third model developed by Recker and collaborators also showed the effectiveness of KLH. 
Bladder carcinoma was induced in Wistar rats using N-butyl-N-(4-hydroxybutyl) 
nitrosamine (BBN). Stimulation of the rats with 12.5 mg of KLH administered intravesically 
and 0.5 mg administered subcutaneously twice weekly after sensitization with 1 mg 
subcutaneous KLH resulted in a reduction in BBN-induced bladder tumors. These results 
confirmed that effective induction of an immune response is important for the control of 
tumor development because immune-suppressed rats treated with cyclosporine A (CsA) 
showed enhanced bladder tumor expansion compared with rats treated with 0.05% BBN 
alone (Recker & Rubben, 1989). A subsequent study distinguished between intravesical and 
subcutaneous application to determine the most effective treatment regime. Five weeks after 
the completion of tumor induction with 0.05% BBN solution, exophytic bladder tumors 
appeared in all control animals. In group 2, which was given KLH via intravesical 
instillation, tumors developed in 73.5% of cases. In group 1, with subcutaneous 
administration, tumors developed in only 50% of cases. The tumor growth was significantly 
slower in group 1 than group 2 (Linn et al., 2000). 
The results described above demonstrated promising potential for the use of KLH in SBC 
therapy. More recently, preclinical studies have proven hemocyanin from Concholepas 
concholepas (CCH) to be a reliable alternative to KLH (Moltedo et al., 2006). C3H/He mice 
were primed with CCH before subcutaneous implantation of MBT-2 cells. Treatment 
consisted of a subcutaneous dose of CCH (1 mg or 100 µg) at different intervals after 
implantation. The results demonstrated a significant antitumor effect, as indicated by 
decreased tumor growth and incidence, prolonged survival and a lack of toxic effects. These 
results were similar to those achieved with KLH.  
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Model Priming1 Via            
Administration 
Therapeutic 
Dosage and 
Schedule2 
Results Reference 
Mouse, MBT-2 Yes  
200 µg 
Intralesional 50 µg 
Days: 1 and 7. 
Significant reduction of 
tumor growth and 
survival with KLH. 
Lamm  
et al.1981 
 No Intralesional Day: 1 KLH presented a minor 
antitumor effect 
compared with BCG. 
Lamm  
et al. 1982 
 Yes 
 
Subcutaneous or 
intralesional 
50 or 200 μg 
Days: 1, 8 and 18 
or 1, 14 and 21. 
KLH do not show 
difference with controls 
in tumor growth or 
animal survival.  
Walsh  
et al. 1983 
 No Intraperitoneal v/s 
intralesional 
50 µg 
 
Intralesional route of 
inoculation of KLH was 
more effective. 
Lau  
et al. 1986 
 No Intravesical 50 µg 
Days: 1 or 6,  
or both. 
Immunotherapy with C. 
parvum and A. sativum 
was more effective than 
KLH. 
Marsh  
et al.1987 
 No Intraperitoneal 50 µg 
Twice weekly for 
3 weeks. 
Better response in the 
animals treated with 
KLH more INF-α. 
Riggs  
et al. 1992 
 Yes 
50 or 100 μg 
Intralesional 50 or 100 μg 
Days: 1, 7 and  
13 or 14. 
Required pre-
immunization of KLH 
and Immucothel to be 
effective. 
Lamm  
et al. 1993a 
 Yes 
50 or 100 μg 
Intralesional 50 or 100 μg 
Days: 1, 7 and  
13 or 14. 
Endotoxin 
contamination of KLH 
was responsible in  
part for the antitumor  
activity. 
Lamm  
et al. 1993b 
 Yes 
200 to 400 µg 
Subcutaneous 1 mg  
Days: 1 to 6 or  
100 µg 
Days: 1, 3, 5,  
7 and 9. 
Significant reduction of 
tumor growth and 
survival with CCH. 
Moltedo  
et al. 2006 
 Yes  
200 µg 
Subcutaneous 100 µg 
Days: 1, 3, 5,  
7 and 9. 
Better antitumor effect 
with  
CCHA subunit than 
CCHB subunit. 
Becker  
et al. 2009 
Mouse, MB-49 Yes 
100 µg 
Intravesical 10 or 100 µg 
Days: 1, 4, 7,  
14 and 21. 
Prior immunization of 
KLH-IA was required to 
elicit antitumor  
activity. 
Swerdlow  
et al. 1994 
Rats, tumor 
induction with 
BBN3 
Yes 
1 mg 
Intravesical and 
subcutaneous 
12.5 mg and 500 
µg 
Twice weekly. 
Reduction of bladder 
tumors with KLH. 
Recker  
et al. 
1989 
 Yes 
1 mg 
Intravesical v/s 
subcutaneous 
500 µg 
Twice weekly for 
8 weeks. 
Subcutaneous route of 
KLH was more effective 
than intravesical route. 
Linn  
et al. 2000 
1 Priming: Usually, around two weeks prior to tumor challenge. 2 Immunotherapy after tumor 
transplantation. 3 BNN: N-butyl-N-(4-hydroxybutyl) nitrosamine 
Table 1. Preclinical studies in different animal models of SBC with KLH or CCH as an 
immunotherapeutic agent. 
www.intechopen.com
 
Hemocyanins in the Immunotherapy of Superficial Bladder Cancer 
 
229 
Later, the individual contributions of the CCHA and CCHB subunits of CCH as 
immunotherapeutic agents in the same bladder cancer model were studied. C3He/He mice 
were subcutaneously primed with CCHA or CCHB; whole CCH and PBS were used as 
positive and negative controls, respectively. After day 15, mice were challenged with a 
subcutaneous injection of 2 x 105 MBT-2 cells, and the antitumor treatment was started; 
treatment consisted of a subcutaneous dose of either subunit or a control on alternate days 
for 9 days. Surprisingly, either subunit alone showed an antitumor effect in the MBT-2 
model. However, the tumor incidence was lower in animals treated with CCHA (44% 
incidence) than with CCHB (60% incidence) or whole CCH (62.5% incidence). Moreover, the 
survival probability increased in mice under immunotherapy with CCHA (69.5%) compared 
with CCHB- (64%), CCH- (60%) and PBS-treated (46.5%) mice. In conclusion, this study 
indicated that the CCHA subunit accounts for the most important immunogenic effects of 
CCH (Becker et al., 2009). Together, these preclinical studies (summarized in Table 1) 
demonstrated that hemocyanins have beneficial effects in animal models of SBC that 
resemble human disease without the negative side effects of BCG (Schenkman & Lamm, 
2004). 
4. Use of hemocyanins in clinical studies of SBC 
Surgical procedures such as transurethral resection (TUR) are commonly used as the first 
option to treat SBC. However, there are some tumors that must be treated by other 
strategies, due to the difficulties of fully removing them and the high risk of recurrence. 
Thus, intravesical administration of chemotherapeutic and biological agents has been 
demonstrated to be an effective method in the early stages of the disease, either to treat an 
existing tumor or to prevent recurrence and tumor progression after TUR (Perabo & Muller, 
2004). BCG is one biological therapy that is used as a non-specific immunostimulant to treat 
several malignant tumors (Edwards & Whitwell, 1974; Milas & Withers, 1976), including 
SBC (Morales et al., 1976). BCG has become the first-line treatment and the most effective 
intravesical immunotherapy, lowering the risk of recurrence to an average of 27% of cases 
(Nseyo & Lamm, 1997). Despite these successful results, BCG therapy causes numerous side 
effects, such as dysuria, urinary frequency, cystitis (90% of cases), hematuria and, in rare 
cases, sepsis, indicating the need for new approaches that provide the same or a better 
response without toxic effects (Lamm, 2003).  
In a 1974 delayed-type hypersensitivity (DTH) experiment to measure the immune 
competence of patients with TCC, Olson and collaborators reported the unexpected result 
that patients subcutaneously primed with 5 mg of KLH and then subcutaneous immunized 
with 200 µg of KLH had a significantly diminished tumor recurrence rate over a study 
period of two years. Those patients that were DTH positive to KLH, and therefore immune 
competent, had almost no recurrences (Olsson et al., 1974). This outstanding effect was 
confirmed many years later in a controlled study of patients in stages Ta and T1 who had 
previously been subject to TUR. In this study, the ability of KLH to prevent tumor 
recurrence was compared to mitomycin C (MMC). The patients were subcutaneously 
immunized with 1 mg of KLH and then received monthly intravesical administrations of 10 
mg of KLH. Only 14% of the patients treated with KLH had recurrences, in contrast to the 
MMC patients, 39% of whom reported recurrences, demonstrating that KLH was 
significantly more effective than MMC (Jurincic et al., 1988).  
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A prospective randomized trial compared the effects of ethoglucid and KLH in patients who 
were unresponsive to the chemotherapeutic treatments, doxorubicin or MMC. The 
recurrence rate and the tumor progression rate for the two therapies showed no statistical 
differences (Flamm et al., 1990). Wishahi et al., reported that the incidence of recurrence in 
patients with TCC associated with urinary schistosomiasis was 15% after KLH treatment 
compared with 77% before therapy (Wishahi et al., 1995). This result was similar to the 
results obtained by Olson et al., (1974) and Jurincic et al., (1998) confirming the outstanding 
immunotherapeutic properties of KLH (Olsson et al., 1974; Jurincic et al., 1988). The efficacy 
of this treatment in patients with carcinoma in situ (CIS) grade 3 was studied in a long-term 
follow-up. The patients received an intravesical instillation of KLH weekly for 6 weeks, 
monthly for 1 year and bimonthly for the following 2 years. Patients who were 
unresponsive to KLH were treated with BCG. CIS long-term remission was observed only in 
a limited number of cases, and most cases progressed over time, indicating the 
aggressiveness of this disease (Jurincic-Winkler et al., 1995a). In Table 2, we summarize the 
clinical studies previously described. 
Currently, Immucothel, a clinical-grade KLH preparation, is being evaluated in a Phase III 
clinical trial in Germany for its efficacy in SBC treatment (Biosyn). The Food and Drug 
Administration (FDA) has also authorized another Phase III trial to evaluate the efficacy and 
safety of KLH BCI-Immune Activator (Intracell, USA) versus doxorubicin in BCG refractory 
or intolerant patients with carcinoma in situ, with or without resected SBC. However, this 
study has been suspended. 
The mechanism associated with the immunotherapeutic effect of KLH in this disease is still 
poorly understood. However, there are immunohistological studies on biopsies of TCC 
patients treated with KLH that show strong cellular activation characterized by the 
infiltration of large numbers of mononuclear cells and CD4+ lymphocytes, and to a lesser 
extent, CD8+ T cells and granulocytes, nine months after the beginning of therapy (Jurincic-
Winkler et al., 1995b). This result suggests that the effect of KLH might be strongly related to 
a non-specific immunostimulation of the immune system leading to the development of an 
antitumor response.  
5. Immunologic mechanisms involved in the immunotherapy of SBC with 
hemocyanins 
Although hemocyanins are widely used as thymus-dependent model antigens, the 
relationship between the structure of hemocyanins and the molecular and cellular basis of 
their immunostimulatory capacity is still largely unknown. Investigations into the antitumor 
effect of hemocyanins in human and murine models of SBC have demonstrated a systemic 
activation of the immune response. In these experiments, priming with hemocyanins is 
crucial for the induction of antitumor activity (Lamm et al., 2000; Moltedo et al., 2006). This 
could partially explain why hemocyanins stimulate the immune system. In patients with 
TCC under intravesical KLH therapy, DTH reactions occur. As mentioned previously, 
studies on biopsies of TCC patients treated with KLH showed a higher increase in CD4+ cell 
infiltration than CD8+ T lymphocytes in the submucosa and urothelial cells (Jurincic-
Winkler et al., 1995b). Currently, we know that such responses are characteristic of Th1 type 
responses, which mediate inflammatory functions critical for the development of cell-
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mediated immune responses (Szabo et al., 2003). Other investigations demonstrated that 
during immunization with KLH, the T CD4+ lymphocyte response showed a mixed profile 
of IL-4 and IFN- with an increase in T CD8+ cells in the lymphatic nodules (Doyle et al., 
1998). 
 
Patients  Control    
Group 
Priming Therapeutic              
Dosage and 
Schedule 
Recurrence                 
Rate 
Reference 
19 10 5 mg  
subcutaneous 
200 µg  
Subcutaneous 
11% Olsson  
et al. 1974 
44 23 1 mg 
subcutaneous 
10 mg  
Intravesical, 
monthly for 21 
months, 
approximately. 
14% Jurincic  
et al. 1988 
84 46 1 mg 
subcutaneous 
30 mg 
Intravesical, 
weekly for six 
weeks and then 
monthly for one 
year. 
55% Flamm  
et al. 1990 
13 Own  
controls 
1 mg 
subcutaneous 
for five days 
until DTH 
10 mg  
Intravesical, for 
seven days. 
15% Wishashi  
et al. 1995 
21 Own 
controls 
No 20 mg  
Intravesical, 
weekly for six 
weeks and then 
monthly for one 
year or bimonthly 
for two years. 
43% of patients 
presented long-
term remission 
57% had to be 
cystectomized 
because of CIS 
progression 
Jurincic-
Winkler 
et al. 1995a 
Table 2. Clinical studies using KLH as an immunotherapeutic agent in SBC patients. 
The fact that the non-specific immunotherapeutic effects of hemocyanins are not due to 
any super-antigen-like activity, but rather rely on adequate priming, strongly suggests 
that their therapeutic properties could be attributable to a bystander effect on the tumor 
due to either a loss of tolerance toward tumor antigens or an enhancement of the immune 
response to the tumor. This kind of response would favor a milieu that augments the 
antigen-specific activity of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cell 
responses. These hypotheses are supported by the observation that IFN- and IL-2 are 
secreted in the regional lymph nodes in response to hemocyanin treatment (Gilliet et al., 
2003; Verdijk et al., 2009). NK cells are strongly stimulated by IL-2 secreted by T 
lymphocytes, leading to their differentiation into lymphokine-activated killer cells (LAK) 
and increasing the destructive elements acting on tumor cells. It has been reported that 
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MBT-2 cells do not grow when they are injected into the bladders of mice treated with a 
combination of IL-2 and the cytotoxic agent cyclophosphamide (Ikemoto et al., 1997). 
Moreover, KLH has been shown to enhance NK cell activity and stimulate IFN- secretion 
in SBC patients (Molto et al., 1991). Our later results confirm these observations; mice 
treated with KLH or CCH increase NK cell activity and serum levels of IFN- (Moltedo et 
al., 2006). This is a very important result because, in primary tumors, IFN- is a tumor 
suppressor cytokine that coordinates T and NK cell activities (Kaplan et al., 1998). Indeed, 
it has been demonstrated that the depletion of NK cells abolishes the immunotherapeutic 
effect of BCG on bladder cancer in mice, confirming that these cells play a key role in the 
destruction of primary tumors (Brandau & Bohle, 2001).  
In addition to the antitumor effect provided by the secretion of IFN-, NK cells can delay 
tumor growth by means of antibody-dependent cell-mediated cytotoxicity (ADCC), which 
induces effector cells to kill bladder tumor target cells. We have observed that, in the MBT-2 
model, intralesional CCH or KLH induce an increase in the humoral immune response 
against cell surface tumor antigens in addition to the CCH or KLH antibody response. 
Biopsies taken from the surrounding bladder tissues in SBC patients treated with KLH 
showed an increase in the B lymphocyte population in the lymph follicles, suggesting that 
humoral mechanism are also involved in the immune response induced by hemocyanins 
(Jurincic-Winkler et al., 1995b). 
Finally, the fact that the immunotherapeutic effects of KLH and CCH on bladder cancer do 
not require an adjuvant raises intriguing questions regarding the means by which 
hemocyanins initiate the non-specific anti-tumor immune response and which cells are 
involved. It is possible that hemocyanins interact with a putative receptor on the cell surface 
of antigen presenting cells, leading to their internalization and processing. A promising 
candidate was the mannose receptor because of the high levels of this sugar residue in KLH 
and CCH and the fact that this receptor is highly expressed in antigen presenting cells. 
However, experiments on endocytosis inhibition performed in human DCs cultured in vitro 
with an anti-mannose receptor antibody and KLH showed that while KLH incorporation by 
DCs was partially inhibited, KLH still promoted the activation and maturation of DCs as 
assessed by the up-regulation of the cell surface expression of Major Histocompatibility 
Complex (MHC) class II and co-stimulatory molecules (Presicce et al., 2008). In contrast, 
Teitz-Tennenbaum and collaborators (2008) demonstrated that murine DCs pulsed with 
KLH for 18 hours in vitro did not undergo DC maturation, a result that is consistent with in 
vivo experiments (Teitz-Tennenbaum et al., 2008; Moltedo et al., 2009) and our current 
results. We observed that DCs internalized (Fig. 3) but did not mature within 72 hours of 
culture in vitro with this protein  
It is not known whether hemocyanins might be processed and presented by bladder tumor 
cells themselves, leading to the stimulation of the cytotoxic killer cell antitumor activity. 
Murine bladder tumor cells have been shown to be able to present BCG antigens to specific 
CD4+ T lymphocytes in a classic MHC Class II (Ia)-dependent fashion (Lattime et al., 1992). 
Experiments performed in our laboratory demonstrated that primary cultures of mouse 
bladder epithelial cells and MBT-2 cells cultured in vitro incorporate hemocyanin; however, we 
did not observe any changes in the expression pattern of MHC I and MHC II antigens (Del 
Campo et al., 2007). In addition, in vitro anti-cancer effects of KLH against breast, esophageal, 
prostate and pancreas cancer has been reported (Riggs et al., 2002), also in melanoma 
(Somasundar et al., 2005), however if this effect have an in vivo implication is unknown. 
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Fig. 3. Incorporation of Concholepas hemocyanin by mouse myeloid dendritic cells cultured 
in vitro, analyzed by transmission electron microscopy. Mouse myeloid DCs of 5th day of 
culture in vitro as described (Inaba et al., 1992), previously isolated by positive selection with 
immunomagnetic beads, and later culture with CCH during different times. A. Dendritic 
cell cultured during 30 minutes with CCH. The photograph shows its characteristic 
superficial membrane process, the nucleus (n), and hemocyanin molecules inside a clear 
vacuole (arrow) that resemble a primary lysosome. B. Because of the large size of CCH, and 
because of its peculiar structure as a hollow cylinder, we were able to identify the presence 
of whole hemocyanin molecules inside secondary lysosome like vesicles (arrows) containing 
membrane debris (Del Campo et al., 2007). 
Macrophages are another potential cell type through which hemocyanins could initiate anti-
tumor immune responses. Indeed, IL-1, a pro-inflammatory cytokine produced by 
activated macrophages, has been shown to be increased in the urine after intravesical 
instillation with KLH in patients with SBC (Jurincic-Winkler et al., 1995c). Similarly, this 
cytokine, in addition to other pro-inflammatory cytokines, has been detected in the urine 
after BCG instillation along with an influx of mononuclear cells into the bladder (Teppema 
et al., 1992; Brandau & Bohle, 2001; Brandau et al., 2001).  
In summary, considering that BCG is a whole organism, whereas KLH or CCH are single 
molecules, it is amazing that it induces a similar response. In both cases, however, it is not 
clear which cytokines and cells contribute directly to the anti-tumor activity and which 
represent a secondary phenomenon. 
6. Conclusions 
Hemocyanins have proven to be safe and useful in the immunotherapy and prophylaxis of 
patients with superficial bladder cancer who have failed or are intolerant to the current BCG 
therapy. Moreover, KLH has been shown to produce a more predictable reaction than BCG, 
eliminating the risk of further infections. Despite the fact that biomedical interest in mollusk 
hemocyanins goes back more than 40 years, the precise molecular and cellular mechanisms 
underlying the non-specific immunostimulatory capacities of KLH and, more recently, 
CCH, are poorly understood. The current evidence shows that these huge proteins can 
induce an inflammatory milieu and activate innate immunity, driving a vigorous antitumor 
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adaptive immune response characterized by long-lasting HLA-DR+ cell infiltration into the 
bladder and the secretion of a Th1-type cytokine profile. 
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